Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TransCode Therapeutics, Inc.
< Previous
1
2
Next >
TransCode Therapeutics CEO Letter to Shareholders
July 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
June 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $7 Million Public Offering
June 09, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
June 06, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
June 06, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
May 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 27, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
April 26, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
April 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics to present at AACR Annual Meeting 2023
April 06, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
April 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
April 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
April 03, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports 2022 Results; Provides Business Update
March 31, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
February 28, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
February 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
February 17, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
February 16, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
January 31, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
December 29, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Withdrawal of Registration Statement
December 06, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
November 30, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
November 14, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
November 09, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
November 07, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
October 26, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
October 13, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
November 15, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
Tickers
RNAZ
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
September 30, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
Tickers
RNAZ
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
September 23, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
Tickers
RNAZ
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.